Literature DB >> 1855689

Biology of pancreatic cancer.

G J Poston1, J Gillespie, P J Guillou.   

Abstract

Pancreatic cancer is the fifth leading cause of death from malignant disease in Western society. Apart from the fortunate few patients who present with a resectable small pancreatic adenocarcinoma, conventional treatment offers no hope of cure and has little palliative value. Over the past two decades major steps have been made in our understanding of the biology of pancreatic growth and neoplasia. This review sets out to explore these advances, firstly in the regulation of normal pancreatic growth, and secondly the mechanism which may be involved in malignant change of the exocrine pancreas. From an understanding of this new biology, new treatment strategies may be possible for patients with pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855689      PMCID: PMC1379000          DOI: 10.1136/gut.32.7.800

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  212 in total

Review 1.  Growth factors and cancer.

Authors:  A S Goustin; E B Leof; G D Shipley; H L Moses
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

2.  Effects of cytotoxic drugs on tumor marker secretion of gastrointestinal/pancreatic carcinomas--comparison of studies in nude mice and in patients.

Authors:  U Klapdor; R Klapdor; M Bahlo; N Franke; M Hirschmann
Journal:  Strahlenther Onkol       Date:  1989-07       Impact factor: 3.621

Review 3.  Oncological applications of somatostatin analogues.

Authors:  A V Schally
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

4.  [Individualization of chemotherapy through in vitro predictive determination of the cytostatic sensitivity of malignant tumors].

Authors:  M Dietel; H Arps; U Bals; A Niendorf; P Henke; M Garbrecht; D Platz; H J Weh; G Thoma; R Klapdor
Journal:  Dtsch Med Wochenschr       Date:  1989-10-27       Impact factor: 0.628

5.  Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.

Authors:  A Zalatnai; A V Schally
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

6.  Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.

Authors:  B Szende; A Zalatnai; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

7.  Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement.

Authors:  A Zalatnai; A V Schally
Journal:  Int J Pancreatol       Date:  1989-03

8.  Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine.

Authors:  C Sumi; D S Longnecker; B D Roebuck; T Brinck-Johnsen
Journal:  Cancer Res       Date:  1989-05-01       Impact factor: 12.701

9.  Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995.

Authors:  J R Upp; D Olson; G J Poston; R W Alexander; C M Townsend; J C Thompson
Journal:  Am J Surg       Date:  1988-01       Impact factor: 2.565

10.  Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer.

Authors:  D González-Barcena; M A Ibarra-Olmos; F García-Carrasco; C Gutiérrez-Samperio; A M Comaru-Schally; A V Schally
Journal:  Biomed Pharmacother       Date:  1989       Impact factor: 6.529

View more
  23 in total

Review 1.  Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1997-10

2.  Atypical acinar cell foci in human pancreas. Morphological and morphometric analysis.

Authors:  J Fang; J Hussong; B D Roebuck; M S Talamonti; M S Rao
Journal:  Int J Pancreatol       Date:  1997-10

Review 3.  Pancreatic cancer: a review of emerging therapies.

Authors:  L Rosenberg
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 4.  On the role of cholecystokinin in pancreatic cancer.

Authors:  M K Herrington; T E Adrian
Journal:  Int J Pancreatol       Date:  1995-04

5.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

Review 6.  Somatostatin and the treatment of pancreatic cancer.

Authors:  G J Poston
Journal:  Ann R Coll Surg Engl       Date:  1994-05       Impact factor: 1.891

7.  Transforming growth factor alpha (TGF-alpha) increases cell number in a human pancreatic cancer cell line but not in normal mouse pancreas.

Authors:  B Kullenberg; C Jansen; N Fredäng; B Ohlsson; J Axelson
Journal:  Int J Pancreatol       Date:  2000-12

8.  Transforming growth factor alpha is trophic to pancreatic cancer in vivo.

Authors:  N Davies; P Kapur; J Gillespie; P J Guillou; G J Poston
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

9.  A cohort study of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States).

Authors:  W Zheng; J K McLaughlin; G Gridley; E Bjelke; L M Schuman; D T Silverman; S Wacholder; H T Co-Chien; W J Blot; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1993-09       Impact factor: 2.506

10.  Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas.

Authors:  C R Boschman; S Stryker; J K Reddy; M S Rao
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.